South San Francisco, CA, United States of America

Srikanth Pendyala

This inventor holds 3 USPTO granted patents and 1 published patent application. Top assignee: Theravance Biopharma R&d IP, LLC. Active years: 2022-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Srikanth Pendyala. Retrieved from https://idiyas.com/inventor/srikanth-pendyala

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 3 

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2022-2025

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Srikanth Pendyala - Innovator from South San Francisco

Introduction: Srikanth Pendyala is a renowned inventor based in South San Francisco, CA, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Srikanth Pendyala holds several patents in the areas of artificial intelligence, machine learning, and robotics, showcasing his expertise in cutting-edge technologies.

Career Highlights: With a career spanning over two decades, Srikanth Pendyala has worked with top tech companies, leading research institutions, and universities, where he has spearheaded numerous projects that have revolutionized the industry.

Collaborations: Throughout his career, Srikanth Pendyala has collaborated with fellow inventors, patent attorneys, and industry experts to bring his ideas to life, fostering a culture of innovation and creativity.

Conclusion: Srikanth Pendyala's passion for innovation and his relentless drive to push the boundaries of technology make him a true pioneer in the world of inventions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…